Search

Your search keyword '"MESH: Precancerous Conditions"' showing total 10 results
Start Over Descriptor "MESH: Precancerous Conditions" Language french
10 results on '"MESH: Precancerous Conditions"'

1. Hyperplasie épithéliale atypique du sein : bilan des connaissances et pratique clinique. [Atypical epithelial hyperplasia of the breast: current state of knowledge and clinical practice]

Author

Lavoué, Vincent, Bertel, Claire, Tas, Patrick, Bendavid, Claude, Rouquette, Sophie, Foucher, Fabrice, Audrain, Odile, Bouriel, Catherine, Levêque, Jean, Service de Biologie, CRLCC Eugène Marquis (CRLCC), Service de Gynécologie et Obstétrique [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-hôpital Sud, De Villemeur, Hervé, Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], and CHU Pontchaillou [Rennes]

Subjects
MESH: Humans, MESH: Hyperplasia, MESH: Mammography, MESH: Immunohistochemistry, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, MESH: Metaplasia, MESH: Estrogen Replacement Therapy, MESH: Estrogens, [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, MESH: Precancerous Conditions, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Early Detection of Cancer, skin and connective tissue diseases, MESH: Female, MESH: Breast Neoplasms
Abstract

International audience; INTRODUCTION: The diagnosis of atypical epithelial hyperplasia (AEH) increases with breast cancer screening. AEH is divided in three groups: atypical ductal hyperplasia, columnar cell lesions with atypia, lobular neoplasia. The management of women with AEH is not consensual because of uncertainty about their diagnosis related to the type of the biopsy sampling (core needle biopsy or surgical excision) and their controversial clinical signification between risk marker and true precursor of breast cancer. MATERIAL AND METHODS: A systematic review of published studies was performed. Medline baseline interrogation was performed with the following keywords: atypical ductal hyperplasia, columnar cell lesions with atypia, lobular neoplasia, core needle biopsy, breast cancer, precursor lesion, hormonal replacement therapy. For each breast lesion, identified publications (English or French) were assessed for clinical practise in epidemiology, diagnosis and patient management. RESULTS: With immunohistochemistry and molecular studies, AEH seems to be precursor of breast cancer. But, epidemiological studies show low rate of breast cancer in women with AEH. AEH were still classified as risk factor of breast cancer. CONCLUSION: Because of high rate of breast cancer underestimation, surgical excision is necessary after the diagnosis of AEH at core needle biopsy. Surgical oncology rules and collaboration with radiologist are required for this surgery. A second operation was not required due to involved margins by AEH (except with pleiomorphic lobular neoplasia) because local control of breast cancer seems to be unchanged. Besides, hormonal replacement therapy for patient with AEH is not recommended because of lack of studies about this subject.

Published
2010
Full Text
View/download PDF

2. [HPV immunization for the prevention of cervical cancer]

Author

Mougin, Christiane, Bourgault-Villada, Isabelle, Coursaget, Pierre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
MESH : Uterine Cervical Neoplasms, Uterine Cervical Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Papillomavirus Vaccines, MESH : Treatment Outcome, MESH: Papillomavirus Infections, Virus Replication, MESH : Antibody Formation, MESH: Immunity, Cellular, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Precancerous Conditions, Humans, MESH: Human papillomavirus 18, MESH : Female, MESH : Human papillomavirus 18, Papillomavirus Vaccines, MESH: Human papillomavirus 16, MESH: Treatment Outcome, MESH : Papillomavirus Infections, Human papillomavirus 16, Immunity, Cellular, MESH: Humans, Human papillomavirus 18, MESH: Virus Replication, Papillomavirus Infections, MESH : Humans, MESH : Human papillomavirus 16, virus diseases, MESH : Immunity, Cellular, MESH: Papillomavirus Vaccines, MESH: Antibody Formation, female genital diseases and pregnancy complications, MESH: Uterine Cervical Neoplasms, MESH : Virus Replication, MESH: Precancerous Conditions, Treatment Outcome, Antibody Formation, Female, MESH: Female, Precancerous Conditions
Abstract

International audience; CONTEXT: Human Papillomaviruses (HPV) infect epithelial cells of the skin and mucosae. Mucosal high-risk HPV types (mainly HPV 16 and 18) are involved in the development of cervical cancer, one of the most common cancers in young women. HPV infection is usually asymptomatic and clears spontaneously, but 10 - 15 % of high-risk HPV infections are persistent and increase the risk of precancerous and cancerous lesions of the cervix. Two HPV vaccines have been licensed to provide protection against cervical cancer. OBJECTIVES: To report the different aspects of HPV infection in order to improve the understanding of the particular problems of HPV vaccination and to review the most recent findings related to HPV vaccines, particularly regarding the protective efficacy of vaccines and the roles of adjuvants and immune response in protection. METHODS: Articles were selected from the PubMed database (National Library of Medicine- National Institute of Health) with the following Keywords "HPV", "Prevention", "HPV vaccines", "Immune response", "Antibody". Abstracts of oral presentations from international meetings were also selected for the more recent findings. a critical analysis of the majority of papers published was undertaken and relevant information summarized. RESULTS: Virus-like particle production by expressing the major protein of the HPV capsid was carried out in the early 90's, leading to the recent development of two HPV vaccines. These vaccines are now licensed in many countries and have been demonstrated to be highly immunogenic. In subjects that are non-infected at the time of vaccination, HPV vaccines are highly effective in preventing persistent HPV 16 - 18 infections (90 %) and precursors lesions of cervical cancer associated with these two HPV types (close to 100 %). Clinical trials have also confirmed that HPV vaccines are well tolerated by recipients. CONCLUSIONS: The present paper is a detailed review published in French on HPV vaccines, their efficacy in the prevention of HPV infections and unresolved questions regarding the use of HPV vaccines. This report also includes biological and immunological information to improve the understanding of HPV vaccination.

Published
2009
Full Text
View/download PDF

3. [Fundamental and translational research on hepatocellular carcinoma in 2008: forces and priorities]

Author

Zucman-Rossi , Jessica, Clément , Bruno, Buendia , Marie-Annick, Lerat , Hervé, Van Beers , Bernard, Bedossa , Pierre, Taieb , Julien, Rosenbaum , Jean, Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Détoxication et réparation tissulaire, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncogenèse et Virologie Moléculaire, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'imagerie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Gènes et pression artérielle (INSERM U772), Collège de France (CdF (institution))-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anatomo-Pathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service d'hépatogastro-entérologie et d'oncologie digestive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Genomique Fonctionnelle des Tumeurs Solides, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -IFR105-Université Paris Diderot - Paris 7 ( UPD7 ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Mondor de recherche biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Beaujon, Gènes et pression artérielle ( Inserm U772 ), Collège de France ( CdF ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), and Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale ( INSERM )

Subjects
MESH : Carcinoma, Hepatocellular, MESH : Liver Neoplasms, test diagnostiques, MESH: Humans, voie de carcinogenèse, MESH : Information Dissemination, MESH : Humans, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Information Dissemination, MESH : Research, digestive system diseases, MESH: Precancerous Conditions, MESH: Research, MESH : Precancerous Conditions, MESH: Liver Neoplasms, MESH : Tumor Markers, Biological, MESH: Tumor Markers, Biological, MESH : Liver Cirrhosis, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, recherche, MESH: Liver Cirrhosis, MESH: Carcinoma, Hepatocellular, carcinome hépatocellulaire
Abstract

International audience; Hepatocellular carcinogenesis is usually the result of a muti-step process. It begins with an exposure to various risk factors; followed by the development of a chronic hepatitis and cirrhosis that is a pre-neoplastic step; and finally after the occurrence of an hepatocellular carcinoma (HCC), different molecular events control aggressiveness of the tumors. The aim of this work was to identify in the international context, forces and priorities of the fundamental and translational HCC research.

Published
2009
Full Text
View/download PDF

4. recherche dans le carcinome hépatocellulaire

Author

Zucman-Rossi, Jessica, Clément, Bruno, Buendia, Marie-Annick, Lerat, Hervé, van Beers, Bernard, Bedossa, Pierre, Taieb, Julien, Rosenbaum, Jean, Zucman-Rossi, Jessica, Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Détoxication et réparation tissulaire, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncogenèse et Virologie Moléculaire, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'imagerie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Gènes et pression artérielle (INSERM U772), Collège de France (CdF (institution))-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anatomo-Pathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service d'hépatogastro-entérologie et d'oncologie digestive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Fibrose hépatique et cancer du foie, and Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
test diagnostiques, MESH: Humans, voie de carcinogenèse, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Information Dissemination, digestive system diseases, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Precancerous Conditions, MESH: Research, MESH: Liver Neoplasms, MESH: Tumor Markers, Biological, recherche, MESH: Liver Cirrhosis, MESH: Carcinoma, Hepatocellular, carcinome hépatocellulaire
Abstract

International audience; Hepatocellular carcinogenesis is usually the result of a muti-step process. It begins with an exposure to various risk factors; followed by the development of a chronic hepatitis and cirrhosis that is a pre-neoplastic step; and finally after the occurrence of an hepatocellular carcinoma (HCC), different molecular events control aggressiveness of the tumors. The aim of this work was to identify in the international context, forces and priorities of the fundamental and translational HCC research.

Published
2009
Full Text
View/download PDF

5. [What's new in the 2004 WHO classification of the lung tumors?]

Author

S, Lantuéjoul, E, Brambilla, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'anatomie et cythologie pathologique, CHU Grenoble-Hôpital Michallon, Université Joseph Fourier - Grenoble 1 (UJF), INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département d'anatomie et cythologie pathologique, CHU Grenoble-Hôpital Michallon-Hôpital Michallon, and Lantuejoul, Sylvie

Subjects
MESH: Carcinoma, Lung Neoplasms, MESH: Humans, Carcinoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, World Health Organization, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH: World Health Organization, MESH: Lung Neoplasms, MESH: Precancerous Conditions, [SDV.CAN] Life Sciences [q-bio]/Cancer, Humans, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Precancerous Conditions, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2008
Full Text
View/download PDF

6. [Non-solid and part-solid pulmonary nodules on CT scanning]

Author

Ferretti, Gilbert, Félix, Laure, Serra-Tosio, Géraldine, Brambilla, Christian, Moro-Sibilot, Denis, Brichon, Pierre Yves, Coulomb, M., Lantuejoul, Sylvie, Pôle d'imagerie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de médecine aiguë spécialisée, CHU Grenoble-Hôpital Michallon-Hôpital Michallon, Département de médecine aiguë spécialisée, CHU Grenoble-Hôpital Michallon, Département de chirurgie thoracique, vasculaire et endocrinienne, Département d'anatomie et cythologie pathologique, and Vesin, Aurélien

Subjects
MESH: Humans, Lung Neoplasms, Solitary Pulmonary Nodule, MESH: Algorithms, MESH: Coin Lesion, Pulmonary, MESH: Lung Neoplasms, MESH: Precancerous Conditions, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Prevalence, Humans, MESH: Lung, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Tomography, X-Ray Computed, Tomography, X-Ray Computed, Lung, Precancerous Conditions, MESH: Prevalence, Algorithms
Abstract

International audience; INTRODUCTION: The entities of non-solid and part-solid pulmonary nodules on CT scan have been recently described.STATE OF ART: Nonsolid and part-solid pulmonary nodules account for between 2.9 and 19% of all pulmonary nodules detected in high-risk patients included in CT screening series for lung cancer. Radio-pathological correlations have shown that the aetiology could be either benign (chronic pneumonia, atypical adenomatous hyperplasia, localized fibrosis) or malignant (broncholoalveolar cell carcinoma, adenocarcinoma, more rarely metastasis). Part-solid or non-solid nodules are more likely to be malignant than solid ones. The doubling time of non-solid nodules can be longer than part-solid ones and even longer than the doubling time of solid nodules. Patient prognosis is related to the proportion of the ground glass component.PERSPECTIVE: The management of these nodules requires prolonged surveillance of nodules less than 10mm in diameter and surgical excision of nodules greater than 10mm persisting on scans between 1 to 3 months after they have been discovered and anti-inflammatory and anti-infectious therapy has been administered.CONCLUSIONS: Nonsolid and part-solid pulmonary nodules found on CT scan warrant a specific diagnostic workup.

Published
2008

7. [New molecular targets in pancreatic cancer]

Author

Torrisani, Jérôme, Bournet, Barbara, Cordelier, Pierre, Buscail, Louis, Simon, Marie Francoise, Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
MESH: Genes, p16, MESH: Angiogenic Proteins, MESH: Genes, p53, MESH: NF-kappa B, MESH: Growth Substances, Mice, MESH: Smad4 Protein, Animals, Humans, MESH: Animals, Genes, Tumor Suppressor, Angiogenic Proteins, MESH: Tumor Suppressor Protein p53, Growth Substances, MESH: Mice, Smad4 Protein, MESH: Humans, Genes, p16, NF-kappa B, MESH: Genes, Tumor Suppressor, Genes, p53, Pancreatic Neoplasms, MESH: Genes, ras, MESH: Precancerous Conditions, Genes, ras, MESH: Pancreatic Neoplasms, Tumor Suppressor Protein p53, Precancerous Conditions
Abstract

International audience; The understanding of the biology of pancreatic carcinoma has greatly benefited from studies of genetic alterations and molecular expression in experimental models as well as in pre-cancerous and cancerous tissues by mean of molecular amplification and large scale transcriptome analysis. P16, TP53, DPC4/Smad4 tumor suppressor pathways are genetically inactivated in the majority of pancreatic carcinomas, whereas oncogenic k-ras is activated. The activating mutation of the K-ras oncogene on codon 12 seems to occur early in pancreatic carcinogenesis and detecting its mutation in tumor samples could have a clinical relevance in term of positive (improvement of current histological diagnosis) and differential diagnosis (versus chronic pancreatitis) of pancreatic cancer. At a late stage of tumor development, an increase of telomerase activity, an over expression of growth factors and/or their receptors (EGF, nerve growth factor, gastrin, bombesin), of proangiogenic factors (VEGF, FGF, PDGF), of invasiveness factors (metalloproteinases, E-cadherin, beta integrin, urokinase and tissue plasminogen activator) occur. All these molecular events contribute to the progression and to the metastatic potential of this carcinoma. New markers and targets are currently studied among microRNA and epigenetics events such as methylation and acetylation. Among all these molecular markers, some are now tested for their potential clinical interest in term of diagnosis or therapeutic target.

Published
2007
Full Text
View/download PDF

8. [Should we vaccinate our daughters against cervical cancer?]

Author

Lansac, J., Rouzier, Roman, Riethmuller, D., Lévêque, Jérémy, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Centre de Physique des Particules de Marseille ( CPPM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Aix Marseille Université ( AMU ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Vaginal Smears, MESH: Humans, MESH: Vaginal Smears, MESH : Humans, MESH : Uterine Cervical Neoplasms, Uterine Cervical Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Papillomavirus Vaccines, MESH : Papillomavirus Vaccines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Primary Prevention, MESH: Uterine Cervical Neoplasms, MESH: Precancerous Conditions, MESH : Precancerous Conditions, MESH: Primary Prevention, Humans, MESH : Vaginal Smears, Female, MESH : Female, MESH : Primary Prevention, Papillomavirus Vaccines, Precancerous Conditions, MESH: Female, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2007
Full Text
View/download PDF

9. [Intraepithelial lesions and neoplasia associated with human papillomavirus infection]

Author

Didier, Riethmuller, Jean-Sébastien, Guerrini, François, Aubin, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Département de dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Adult, Skin Neoplasms, MESH: Vaginal Smears, MESH : Uterine Cervical Neoplasms, Uterine Cervical Neoplasms, Bowen's Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cervix Uteri, MESH : Cervical Intraepithelial Neoplasia, MESH: Papillomavirus Infections, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Precancerous Conditions, Humans, MESH : Female, MESH : Carcinoma, Squamous Cell, Vaginal Smears, MESH : Papillomavirus Infections, MESH: Humans, MESH : Colposcopy, MESH: Skin Neoplasms, Papillomavirus Infections, MESH : Skin Neoplasms, MESH : Humans, MESH : Bowen's Disease, virus diseases, MESH: Adult, MESH: Carcinoma, Squamous Cell, MESH: Cervix Uteri, MESH : Adult, Uterine Cervical Dysplasia, female genital diseases and pregnancy complications, MESH: Uterine Cervical Neoplasms, MESH: Bowen's Disease, MESH: Precancerous Conditions, Colposcopy, MESH : Cervix Uteri, Carcinoma, Squamous Cell, MESH : Vaginal Smears, Female, MESH: Colposcopy, MESH: Cervical Intraepithelial Neoplasia, Precancerous Conditions, MESH: Female
Abstract

International audience; Anogenital lesions induced by human papillomaviruses (HPV) are due to both high-risk HPV types involved in carcinogenesis of the cervix (and also, to a lesser extent, of the vulva, anus and vagina) and to low-risk HPV types that cause external genital warts in the perianal region, perineum, vulva and vagina (less often the cervix). Cervical cancer is thus virus-induced, and there is a continuum from intraepithelial lesions to invasive cancer. This offers the opportunity to screen cervical smears for cytological abnormalities or to detect high-risk HPV infection by molecular methods. Although the causal link between human genital papillomavirus infection and cervical neoplasia is well established, the role of beta-HPV in non melanoma skin cancers is unclear.

Published
2007

10. [Fluorescence endoscopy of the respiratory tract]

Author

Thiberville, Luc, Salaün, Mathieu, Lachkar, Sammy, Breton, Céline, Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), and Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
Lung Neoplasms, MESH: Humans, MESH: Precancerous Conditions, Bronchial Neoplasms, MESH: Fluorescence, Humans, Endoscopy, Precancerous Conditions, Fluorescence, MESH: Bronchial Neoplasms, MESH: Endoscopy, MESH: Lung Neoplasms
Abstract

International audience; Autofluorescence endoscopy has been used for more than 10 years in the diagnosis of early lung cancers and precancerous lesions of the bronchial tree. The technique has been extensively evaluated during the past decade and two recent large randomised studies have shown a 2 to 5 times increase in the detection of high grade pre-cancerous lesions compared with conventional white light endoscopy. This paper reviews the principal applications and results of the use of autofluorescence endoscopy in high risk individuals as well as innovative endoscopic approaches using the fluorescent properties of the respiratory tract.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results